In this episode, I discuss corneal disease and treatments with David Eveleth, PhD, the founder, president and CEO of Trefoil Therapeutics. Brought to you by Alcon ·       Welcome to another exciting episode of Eye Care insider :14 ·       Intro David Eveleth, PhD :47 ·       Eveleth’s background 1:05 ·       What’s the treatment landscape now for corneal diseases and where are we falling short for patients? 2:59 ·       The origins of Trefoil Therapeutics 7:27 ·       FGF-1: Is it just important in the endothelium or is it also important in the epithelium? 11:47 ·       What is your current lead investigational candidate? 14:01 ·       When do you expect another read out of clinical data? 21:47 ·       An adjunctive therapy with cataract surgery 18:27 ·       What is the timeline of administration to patients? 19:24 ·       When do you expect a readout of clinical data? 20:49 ·       Is it possible to use this also for the epithelium? 21:39 ·       What are the most important challenges facing the ophthalmic industry? What is the most important factor to look for? 24:07 ·       For more information about David Eveleth, PhD, and Trefoil Therapeutics, visit www.trefoiltherapeutics.com 25:53 ·       Corneal disease can be fixed and better vision is possible 26:44 ·       Thanks for listening 27:04 We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can find follow Trefoil Therapeutics on Twitter @TrefoilThera. David Eveleth, PhD, is the president and CEO of Trefoil Therapeutics. Disclosures: Eveleth is the founder, CEO and shareholder of Trefoil Therapeutics. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.

In this episode, I chat with Nancy Lurker, CEO and board director, about EyePoint Pharmaceuticals and their latest treatments and trials. Brought to you by Alcon ·       Welcome to another exciting episode of Eye Care insider :13 ·       Intro Nancy Lurker :22 ·       Lurker’s background :58 ·       EyePoint Pharmaceuticals: the origin and transition 2:29 ·       Yutiq and long-acting drug delivery systems 6:07 ·       Additional indications for Yutiq 8:30 ·       What is the key factor in delivering this longer durability? 16:13 ·       Any consideration of looking at superiority of visual acuity and anatomical OCT gains? 21:47 ·       Is the primary focus wet AMD? Or are you also looking at NPDR and DME as potential indications? 24:19 ·       Investor information and neural protection data 29:01 ·       What is the most important issue that the field of ophthalmology is currently facing? 30:38 ·       Thanks for listening 32:37 We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can find Nancy Lurker at @EyePointCEO and @EyePointPharma. Nancy Lurker is the board director and CEO of EyePoint Pharmaceuticals. Disclosures: Lurker is the board director and CEO of EyePoint Pharmaceuticals. Mali reports he is founder and CEO of Mali Enterprises; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.

In this episode, I discuss Samsara Vision’s SING IMT and its benefits of vision improvement for patients with AMD with Rebecca Kammer, OD, PhD. Brought to you by Alcon ·       Welcome to another exciting episode of Eye Care insider :14 ·       Intro for Rebecca Kammer, OD, PhD :27 ·       Dr. Kammer’s background 1:28 ·       Defining late-stage AMD patients and treatments available 5:11 ·       The SING IMT 9:46 ·       US Concerto Study Website – to learn more about the study 13:13 ·       Visual acuity and the SING IMT 13:48 ·       US trial, recruitment and patient eligibility 17:18 ·       Contact toll-free 1-866-393-3767 discuss eligibility, participation and questions 20:39 ·       SING IMT as an option for patients 22:55 ·       Thanks for listening 27:30 We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can reach Dr. Kammer at rkammer@samsaravision.com. Rebecca Kammer, OD, PhD, is the vice president of worldwide clinical and medical affairs for Samsara Vision, Inc., an adjunct professor at University of California, Irvine and a diplomate in low vision of the American Academy of Optometry. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI. Kammer reports being a clinical advisor to Biovisics and Eyedaptic.

In this episode, I share my top five predictions for 2023 in the field of ophthalmology. Brought to you by Alcon Welcome to another exciting episode of Eye Care insider :52My review of the top five predictions in ophthalmology 1:03Prediction #1 – Vabysmo and anti-VEGF market 1:53Prediction #2 – FDA approval for GA treatment 4:26Prediction #3 – SNAPS eye shield for ocular protection 6:06Prediction #4 – biosimilars and the ophthalmic therapeutic marketplace 10:08Prediction #5 – retina analytical tools 12:27Thanks for listening 14:30 We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.

In this episode, I share my thoughts about the five greatest innovations of the 21st century in the field of ophthalmology and how they have changed patient outcomes for the better. Brought to you by Alcon Welcome to another exciting episode of Eye Care insider :50My review of the top five innovations in ophthalmology 1:02Greatest Innovation #1 – anti-VEGF medications 2:06Greatest Innovation #2 – intraocular lens implantation technology 3:26Greatest Innovation #3 – electronic medical records 4:08Greatest Innovation #4 – optical coherence tomography 5:48Greatest Innovation #5 – telemedicine 6:35Thanks for listening 7:44 We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular  Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

In this episode, I share my review of the hot topics from the AAO 2022 annual meeting and share my thoughts on the new data shared about drug trials and treatments. Brought to you by Alcon Welcome to another exciting episode of Eye Care insider :53My review of the hot topics from the AAO 2022 annual meeting 2:20Hot Topic #1 – wet AMD treatments 2:40Hot Topic #2 – high-dose Eylea 6:20Hot Topic #3 – geographic atrophy treatments 10:24Thanks for listening 16:04 We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

In this episode, I share my preview of the hot topics for the upcoming AAO 2022 annual meeting, including my thoughts on ocular gene therapy and new treatments in the works. Welcome to another exciting episode of Eye Care insider :52My preview of hot topics for the upcoming AAO 2022 annual meeting 1:04Hot Topic #1 – new treatments for dry AMD or geographic atrophy 2:43Hot Topic #2 – wet AMD management 5:55Hot Topic #3 – ocular gene therapy 7:56Hot Topic #4 – biosimilars 9:17Thanks for listening 11:22 We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

In this episode, Jose O. Segura, wealth management advisor and certified business exit planner, discusses establishing objectives within financial planning and organization, how to diversify your portfolio in ever-changing markets and more. Intro :38Welcome to another episode of Eye Care insider :52About Jose Segura 1:03For people that are listening for the first time, do you mind giving a brief of your background? 1:32What are, in your opinion, some best practices in regard to financial planning? 2:58Process for financial organization and seeking out advisors. 10:09Can you talk about the importance of portfolio diversification? 12:07Importance of maintaining your overall focus on financial planning and strategies when markets are effected. 16:56Could you give us one pearl for our listeners, or one key economic update that you think would be really important to the current economic situation right now? 18:49Thank you Jose 23:09Any final words to our listeners? 23:11Outro 23:35   Jose O. Segura, is a wealth management advisor and certified business exit planner. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. For more information about Segura, visit www.joseosegura.com, reach him by email at jose_segura@wagllc.com, or call 518-867-3210 x104. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Segura reports he is a registered Representative and Financial Advisor of Park Avenue Securities LLC (PAS), 355 Lexington Avenue, 9 Fl., New York, NY 10017, 212-541-8800.

In this episode, Ashlie Leal, director of ophthalmology at FundamentalVR, discusses their fully immersive surgical training products, how virtual reality plays a role in training surgeons and more. Intro :38Welcome to another episode of Eye Care insider :52About Ashlie Leal 1:00Give me a little bit of your background – how you got into this industry and your role at FundamentalVR? 1:33Can you give our listeners some background about FundamentalVR as a company, and why should eye care professionals start paying attention to your company? 2:56Do you target training programs? … Is there a certain focus to your company in regards to demographics? 4:12Is there any way you can describe [your virtual reality products] or any current product offers that you have that apply to eye care professionals? 7:30You’re using a headset and the two arms. Is that all you would need, or would you need some sort of base mannequin head with an eyeball simulation? 9:25You can do it anywhere, theoretically? And you can simulate different MIGS equipment and different ocular lens implants based on the tech simulating that equipment? 10:59So, the simulation is able to carry out these multiple, intricate steps? 12:03Is there current gene therapy that is utilizing your technology? Do you have a relationship with them in the sense that you provide the surgeons with the virtual reality simulations? 12:49Do you have any sort of data or any procedure done with virtual reality improving complication rate and efficiency? 14:02What does the future look like for virtual reality? What would you say is the major challenge, or what does your company hope to accomplish in the next few years or the decade? 15:30What’s that process look like for a company to approach you for virtual reality offering to train on a new device? How long does that process take, and what are the steps to assimilate their product into your technology? 17:14If someone wants to learn more, how can they contact you or your company for more information? 19:13Congratulations Ashlie and FundamentalVR 19:39Any final words to our listeners? 20:02Outro 20:39   Ashlie Leal is director of ophthalmology, FundamentalVR. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Leal can be reached on LinkedIn or at www.fundamentalsurgery.com.    Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Leal reports she is director of ophthalmology at FundamentalVR.

In this episode, Allisa Song, a medical student and the CEO and co-founder of Nanodropper, discusses the inception of the device, how it can benefit the eye care industry and more. Intro :38Welcome to another episode of Eye Care insider :52About Allisa Song 1:01I want to hear your story about the history about the Nanodropper – how you came to this idea; what problem you were trying to solve; and how you got here? 2:02What are the major advantages of your product? Why doesn’t our standard bottle function properly like that? 5:06Can this go on every eyedrop bottle? 6:49Is there any sort of data that we can look at that shows how much volume of the prescription is saved? 7:51Can you talk to me about how industry has taken this? What is your take on how they feel about your product? 12:15How are you distributing your product to the consumers and to the masses? What are your channels to get the product out there? 15:36What do you think the future holds for Nanodropper? Where do you see this going in the next 3 to 5 years? 17:04Is there any information that you can provide to our listeners can go to and learn more about your story? 18:23Congratulations again Allisa 19:03You’ll be graduating from medical school pretty soon? 19:15Any final words to our listeners? 19:50Outro 20:26   Allisa Song, is a Mayo Clinic Alix School of Medicine medical student and the CEO and co-founder of Nanodropper. Song is a serial entrepreneur and inventor with a background in Clean Tech, neuroscience, and harm reduction. In addition to her proven track record of successful fundraising, she has led her teams to dozens of business and design awards, including her most recent USPTO Collegiate Inventor medal awarded by the National Inventors Hall of Fame.  We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Song can be reached at support@nanodropper.com.   Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Song is the CEO and co-founder of Nanodropper and serves as an advisor for Bedo Solutions.

In this episode, Arthur Benjamin, MD, discusses dry eye treatment and trends, the challenges dry eye patients and the eye care professionals treating them and more. Intro :37Welcome to another episode of Eye Care insider :51About Arthur Benjamin, MD 1:02I wonder if you could talk about your training and what you currently do now? 1:39Could you talk about what you’ve seen throughout the years and what you’ve seen in the trends in dry eye and how it has expanded in the population? 2:56What is your current algorithm for someone with dry eye? How do you manage that? 5:01Once you do determine they have moderate dry eye where do you start with the patient or the treatment paradigm? 7:00With the OptiLight treatment option … what do you tell patients? What should they be expecting? 9:54I recently saw that there’s been a campaign from OptiLight involving Mandy Moore. Could you talk about that campaign and discuss it a little bit further? 12:54What do you think is the most important topic or issue or challenge that are facing dry eye patients today or eye care professionals treating patients with dry eye? 16:07What a fascinating discussion 17:43Any last words? 17:55Outro 18:09 Arthur Benjamin, MD, is a clinical assistant professor at the Jules Stein/Doheny Eye Institute at UCLA’s Geffen School of Medicine and is in private practice at Benjamin Eye Institute.   We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Dr. Benjamin can be contacted by going to BenjaminEye.com. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Benjamin reports no relevant financial disclosures.

In this episode, Dhruvin Patel, MCOptom, discusses the short- and long-term effects of blue light on our eyes, how the pandemic has exacerbated these effects and how his company, Ocushield, is looking to help protect eyes from blue light. Intro :01Patel’s introduction and background :43The science and necessity behind blue light blocking filters 5:35Short-term effects of blue light on the eyes 7:15Long-term effects of blue light on the eyes 8:24Are eye care professionals doing enough to promote blue light protection? 12:11Has the pandemic affected the demand/awareness of blue light related products? 14:25Ocushield filters: what they are and how to get them 16:15What makes Ocushield unique in the blue light/ophthalmic landscape? 19:03How to contact Dr. Patel and Ocushield 20:31Patel’s final thoughts on our visual system and the importance of protecting it 21:11Outro 22:01 Dhruvin Patel, MCOptom, is an optometrist and the founder of Ocushield. You can send your comments/questions directly to him at www.ocushield.com.  Follow him on Instagram, Facebook and Twitter @getocushield. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Patel is founder of Ocushield.

In this episode I share my top 5 predictions in ophthalmology for 2022, including my thoughts on the future of COVID-19 and ocular gene therapy. Welcome to another exciting episode of Eye Care insider :50My top 5 predictions for 2022 1:16Prediction #1 – on COVID-19 1:27Prediction #2 – on wet AMD 2:43Prediction #3 – on ocular gene therapy 4:05Prediction #4 – on geographic atrophy 5:05Prediction #5 – on ophthalmology media platforms 7:23Thanks for listening 9:20 We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can contact Mogan by going to the company’s website, www.parkplacepayments.com or at Linkedin. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

In this episode, Jennifer L. Mogan, MD, discusses her path into medicine, the importance of the credit card process and how it can be beneficial for eyecare practices. Welcome to another exciting episode of Eye Care insider :14What led to the inception of the ‘Doctorpreneurship’ series? :29About Mogan 2:16The interview 2:47Give us an idea of your background, your training and why you went to medicine? 3:12How in the world did you get involved with credit card processing? 4:12Can you summarize the whole credit card processing process? Why should eye care professional or anybody in health care be aware of this structure and how will it affect their bottom line? 5:51So, what are you finding in the market? Are physicians aware of this, are they not? And if they’re not, how much is this potentially costing a practice? 11:37How can they implement these strategies in practice or what services can your company offer eyecare professionals in helping to solve this problem? 12:46Have you seen an uptake in business recently because of practices trying to minimize their expenses by lowering these rates? 13:57How to find Mogan 14:35What do you love about being a Doctorpreneur and do you have any advice or pearls for the audience? 15:02Thank you, Dr. Mogan for all your great advice and tips 16:07 Jennifer L. Mogan, MD, is an anesthesiology specialist with Rochester Regional Health and a senior account specialist for Park Place Payments.   We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can contact Mogan by going to the company’s website, www.parkplacepayments.com or at Linkedin. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Mogan is a senior account specialist for Park Place Payments.

In this episode, Sue Washer, BS, MBA, discusses gene therapy in ophthalmology, ATGC’s clinical trial progress, as well as current and future challenges faced by both the cell therapy industry and ophthalmology. Welcome to another exciting episode of Eye Care insider :13About Washer 1:51Can you discuss what is gene therapy? How does it work on a basic level? 4:53How do companies like AGTC make gene therapy work for diseases that may not affect as many people but still make it financially successful for investors? 7:11Could you talk about where you are in the X-Linked Retinitis Pigmentosa candidate trials? 11:08Is there an estimated timeline that you have for initial data read out? 14:56You have another candidate for achromatopsia … I was reading you had some new data released. Could you go into more details about that? 16:23What do you think is the most important topic or challenge you see facing the gene therapy industry and ophthalmology today and in the future? 20:56Thank you so much for your insight into this fascinating topic 23:22How to find out more about AGTC 23:31Thank you for listening 24:15 Sue Washer, BS, MBA is the president and chief executive officer of AGTC. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can contact AGTC through the company’s website at www.atgc.com. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Washer is the president and CEO of AGTC.

In this episode, the third of a three-part series, John B. Pinto discusses some of the future megatrends expected for ophthalmic practices, challenge practices may face in the future, and more. Intro :13What you think the megatrends are going to be over the next decade or so in the ophthalmic practices :50What do you think is the most important topic or issue or challenge facing ophthalmic practices now and in the future? 4:46If our listeners wanted to learn more, what’s the best way to contact you? 10:02I really appreciate you and all your great advice 10:47Any final words? 11:00Thank you so much John, I appreciate it 11:16 John B. Pinto is president of J. Pinto & Associates, Inc. He is also a practice consultant and the author of several books on ophthalmic practice management, including John Pinto’s Little Green Book of Ophthalmology, UP (with Corinne Wohl), Simple, and Ophthalmic Leadership. UP: Taking Ophthalmic Administrators and Their Management Teams to the Next Level of Skill, Performance and Career Satisfaction, Second Edition is a powerful, practical workbook by Corinne Wohl, MHSA, COE and John B. Pinto designed to take ophthalmic administrators and practice managers to the next level of their careers, offering practical tips, concrete advice, and a step-by-step guide for any hurdle they face. Available now for purchase at slackbooks.com/management. Receive 20% off with promo code PINTO20. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: The Wyanoke Group is the parent company of Healio and SLACK Books. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

In this second episode of a three-part series, John B. Pinto discusses the job market for early-career professionals and new graduates, his perspective on what ophthalmologists have learned from the pandemic and the role telemedicine will play in the future of ophthalmology. Intro :14What is the current negotiation position in the market for early-career and new graduate ophthalmic practice physicians? :41I’d love to hear your perspective on what we have learned about our practices after a year of this pandemic 3:35How is the telemedicine trend going now? Is telemedicine here to stay? 11:09Tell us about your upcoming book and your insight into it? 12:59Stay tuned for the next episode of this special three-part miniseries 17:38 John B. Pinto is president of J. Pinto & Associates, Inc. He is also a practice consultant and the author of several books on ophthalmic practice management, including John Pinto’s Little Green Book of Ophthalmology, UP (with Corinne Wohl), Simple, and Ophthalmic Leadership. UP: Taking Ophthalmic Administrators and Their Management Teams to the Next Level of Skill, Performance and Career Satisfaction, Second Edition is a powerful, practical workbook by Corinne Wohl, MHSA, COE and John B. Pinto designed to take ophthalmic administrators and practice managers to the next level of their careers, offering practical tips, concrete advice, and a step-by-step guide for any hurdle they face. Available now for purchase at slackbooks.com/management. Receive 20% off with promo code PINTO20. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: The Wyanoke Group is the parent company of Healio and SLACK Books. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

In this episode, the first of a three-part series, John B. Pinto discusses how he got started in ophthalmic practice management, shares an historical perspective on the field, plus his advice for physicians. Intro :16About John Pinto :54On Pinto’s background, why he went into the ophthalmic practice management industry 1:39Can you give listeners a historical perspective of how has ophthalmic practice management changed or evolved over the last 40 years? 7:13What is the current state of ophthalmic practice management in America today? 13:11Could you give a key pearl for how to handle practice management as an early- or mid-career physician as well as a late-career/ retirement-age physician? 16:02In your experience, what would you say would be the average age of full retirement in ophthalmology? 23:56Stay tuned for the next episode of this special three-part miniseries 27:19 John B. Pinto is president of J. Pinto & Associates, Inc. He is also a practice consultant and the author of several books on ophthalmic practice management, including John Pinto’s Little Green Book of Ophthalmology, UP (with Corinne Wohl), Simple, and Ophthalmic Leadership. UP: Taking Ophthalmic Administrators and Their Management Teams to the Next Level of Skill, Performance and Career Satisfaction, Second Edition is a powerful, practical workbook by Corinne Wohl, MHSA, COE and John B. Pinto designed to take ophthalmic administrators and practice managers to the next level of their careers, offering practical tips, concrete advice, and a step-by-step guide for any hurdle they face. Available now for purchase at slackbooks.com/management. Receive 20% off with promo code PINTO20. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: The Wyanoke Group is the parent company of Healio and SLACK Books. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

In this episode, Rick Eiswirth, president and CEO of Alimera Sciences, shares the latest on the phase 4 New Day study of Iluvien, as well as his predictions for the future of ophthalmology. Intro :13In this episode :18About Rick Eiswirth :23What’s your background? How did you get into the ophthalmology industry? 0:51What are the benefits of Iluvien (fluocinolone acetonide intravitreal implant, Alimera Sciences)? Is this an ideal treatment for 2021? 3:36How do you get retina specialists more onboard with using intravitreal steroids earlier, given anti-VEGFs’ predominance? 6:26Can you tell us more about the New Day trial? 8:10Which trial outcome would be considered a success for Iluvien? 11:58Do you anticipate a cost savings? 13:58What’s the status of the New Day trial? 15:15How has COVID changed the industry landscape in ophthalmology? 16:20Are there any new products in the pipeline? 18:38Iluvien is approved in other countries for uveitis 20:36What have you seen from retina specialists; are there longer efficacy rates? 22:10What do you think is the most important challenge the ophthalmic community will face in the future? 23:17Thanks for listening 24:36 Rick Eiswirth is president and CEO of Alimera Sciences. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: Eiswirth is president and CEO of Alimera Sciences. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. McCabe reports consultant relationships with Alcon, Allergan, Bausch and Lomb, Dompe, EyePoint Pharmaceuticals, Ivantis, Novartis, Ocular Therapeutix, Omeros, Sight Sciences and Zeiss. She reports research roles with Alcon, Allergan, Bausch and Lomb, EyePoint Pharmaceuticals, Glaukos, Ivantis, Johnson & Johnson, Ocular Therapeutix and Ora. She also reports an investor relationship with Ocular Innovations.

In this episode, Cathleen M. McCabe, MD, chief medical officer of Eye Health America, shares her insights and perspectives on intraocular lenses, MIGS, dry eye and more. Intro :14In this episode :21About Cathleen M. McCabe, MD :28What is your favorite intraocular lens implant to use and why? 2:24What is your favorite minimally invasive glaucoma surgery (MIGS) to use and why? 4:03What is your favorite dry-eye treatment to use and why? 4:49What’s your preferred technique for secondary IOLs? 6:29How has the role of women in ophthalmology changed throughout the years? 8:46How did you get involved with international work? How has the pandemic affected this? 10:55Tell us about your mission work. What are you currently involved in? 12:54What is the most important topic/issue/challenge facing ophthalmology now or in the future? 15:11Final words from Dr. McCabe 16:46 Cathleen M. McCabe, MD, is chief medical officer of Eye Health America; medical director of The Eye Associates and president of Outpatient Ophthalmic Surgery Society. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. To learn more about the Global Education & Research Society of Ophthalmology (or GERSO), visit https://www.gerso.org. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. McCabe reports consultant relationships with Alcon, Allergan, Bausch and Lomb, Dompe, EyePoint Pharmaceuticals, Ivantis, Novartis, Ocular Therapeutix, Omeros, Sight Sciences and Zeiss. She reports research roles with Alcon, Allergan, Bausch and Lomb, EyePoint Pharmaceuticals, Glaukos, Ivantis, Johnson & Johnson, Ocular Therapeutix and Ora. She also reports an investor relationship with Ocular Innovations.